Methylation status and neurodegenerative markers in Parkinson disease

Clinical Chemistry

Volumn 55, Issue 10, 2009, Pages 1852-1860

  Obeid, Rima ^a   Schadt, Achim ^a   Dillmann, Ulrich ^a   Kostopoulos, Panagiotis ^a   Fassbender, Klaus ^a   Herrmann, Wolfgang ^a  

^a SAARLAND UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA SYNUCLEIN; AMYLOID BETA PROTEIN[1-42]; AMYLOID PRECURSOR PROTEIN; BIOLOGICAL MARKER; CYANOCOBALAMIN; DOPAMINE RECEPTOR STIMULATING AGENT; FOLIC ACID; HOMOCYSTEINE; LEVODOPA; METHYLMALONIC ACID; PYRIDOXINE; S ADENOSYLHOMOCYSTEINE; S ADENOSYLMETHIONINE;

ADULT; AGED; AMINO ACID BLOOD LEVEL; AMINO ACID METABOLISM; ARTICLE; BIOACCUMULATION; BRAIN DEGENERATION; CELL LEVEL; CORRELATION ANALYSIS; CREATININE BLOOD LEVEL; ECHOENCEPHALOGRAPHY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; METHYLATION; PARKINSON DISEASE; PROTEIN BLOOD LEVEL; QUANTITATIVE ASSAY; SCORING SYSTEM; SUBSTANTIA NIGRA; THROMBOCYTE; VITAMIN BLOOD LEVEL;

AGED; ALPHA-SYNUCLEIN; AMYLOID BETA-PEPTIDES; AMYLOID BETA-PROTEIN PRECURSOR; BIOLOGICAL MARKERS; BLOOD PLATELETS; COGNITION DISORDERS; FEMALE; FOLIC ACID; HOMOCYSTEINE; HUMANS; MALE; METHYLATION; MIDDLE AGED; NERVE DEGENERATION; PARKINSON DISEASE; PEPTIDE FRAGMENTS; S-ADENOSYLHOMOCYSTEINE; S-ADENOSYLMETHIONINE; SUBSTANTIA NIGRA; VITAMIN B 6;

EID: 70349678703     PISSN: 00099147     EISSN: 15308561     Source Type: Journal    
DOI: 10.1373/clinchem.2009.125021     Document Type: Article

References (40)

1. Cookson MR. The biochemistry of Parkinson's disease. Annu Rev Biochem 2005;74:29-52.
2. Blandini F, Fancellu R, Martignoni E, Mangiagalli A, Pacchetti C, Samuele A, Nappi G. Plasma homocysteine and L-dopa metabolism in patients with Parkinson disease. Clin Chem 2001;47:1102-1104 (Pubitemid 32493598)
3. Yasui K, Kowa H, Nakaso K, Takeshima T, Nakashima K. Plasma homocysteine and MTHFR C677T genotype in Levodopa-treated patients with PD. Neurology 2000;55:437-440 (Pubitemid 30650089)
4. Zoccolella S, Lamberti P, Iliceto G, Diroma C, Armenise E, Defazio G, et al. Plasma homocysteine levels in L-dopa-treated Parkinson's disease patients with cognitive dysfunctions. Clin Chem Lab Med 2005;43:1107-1110 (Pubitemid 41581969)
5. Muller T, Renger K, Kuhn W. Levodopa-associated increase of homocysteine levels and sural axonal neurodegeneration. Arch Neurol 2004;61:657-660 (Pubitemid 38637680)
6. O'Suilleabhain PE, Sung V, Hernandez C, Lacritz L, Dewey RB, Jr., Bottiglieri T, az-Arrastia R. Elevated plasma homocysteine level in patients with Parkinson disease: motor, affective, and cognitive associations. Arch Neurol 2004;61:865-868
7. Yasui K, Nakaso K, Kowa H, Takeshima T, Nakashima K. Levodopa-induced hyperhomocysteinaemia in Parkinson's disease. Acta Neurol Scand 2003;108:66-67
8. Liu XX, Wilson K, Charlton CG. Effects of L-dopa treatment on methylation in mouse brain: implications for the side effects of L-dopa. Life Sci 2000;66:2277-2288 (Pubitemid 30256628)
9. Cooper AA, Gitler AD, Cashikar A, Haynes CM, Hill KJ, Bhullar B et al. Alpha-synuclein blocks ER-Golgi traffic and Rab1 rescues neuron loss in Parkinson's models. Science (Wash DC) 2006;313:324-328 (Pubitemid 44480951)
10. Hamilton RL. Lewy bodies in Alzheimer's disease: a neuropathological review of 145 cases using alpha-synuclein immunohistochemistry. Brain Pathol 2000;10:378-384
11. Tsigelny IF, Crews L, Desplats P, Shaked GM, Sharikov Y, Mizuno H et al. Mechanisms of hybrid oligomer formation in the pathogenesis of combined Alzheimer's and Parkinson's diseases. PLoS One 2008;3:e3135.
12. Faucheux BA, Bonnet AM, Agid Y, Hirsch EC. Blood vessels change in the mesencephalon of patients with Parkinson's disease. Lancet 1999;353:981-982 (Pubitemid 29132612)
13. Kang J, Lemaire HG, Unterbeck A, Salbaum JM, Masters CL, Grzeschik KH, et al. The precursor of Alzheimer's disease amyloid A4 protein resembles a cell-surface receptor. Nature 1987;325:733-736 (Pubitemid 17054046)
14. Ponte P, Gonzalez-DeWhitt P, Schilling J, Miller J, Hsu D, Greenberg B, et al. A new A4 amyloid mRNA contains a domain homologous to serine proteinase inhibitors. Nature 1988;331:525-527 (Pubitemid 18064375)
15. Stabler SP, Lindenbaum J, Savage DG, Allen RH. Elevation of serum cystathionine levels in patients with cobalamin and folate deficiency. Blood 1993;81:3404-3413 (Pubitemid 23172927)
16. Gellekink H, van Oppenraaij-Emmerzaal D, van RA, Struys EA, den HM, Blom HJ. Stable-isotope dilution liquid chromatography-electrospray injection tandem mass spectrometry method for fast, selective measurement of S-adenosylmethionine and S-adenosylhomocysteine in plasma. Clin Chem 2005;51:1487-1492 (Pubitemid 41060882)
17. Gaenslen A, Unmuth B, Godau J, Liepelt I, Di SA, Schweitzer KJ, et al. The specificity and sensitivity of transcranial ultrasound in the differential diagnosis of Parkinson's disease: a prospective blinded study. Lancet Neurol 2008;7:417-424
18. Kazmierczak A, Strosznajder JB, Adamczyk A. α-Synuclein enhances secretion and toxicity of amyloid beta peptides in PC12 cells. Neurochem Int 2008;53:263-269
19. Obeid R, Herrmann W. Mechanisms of homocysteine neurotoxicity in neurodegenerative diseases with special reference to dementia. FEBS Lett 2006;580:2994-3005. (Pubitemid 43744523)
20. Lamberti P, Zoccolella S, Iliceto G, Armenise E, Fraddosio A, de MM, Livrea P. Effects of Levodopa and COMT inhibitors on plasma homocysteine in Parkinson's disease patients. Mov Disord 2005;20:69-72. (Pubitemid 40277507)
21. Valkovic P, Benetin J, Blazicek P, Valkovicova L, Gmitterova K, Kukumberg P. Reduced plasma homocysteine levels in Levodopa/entacapone treated Parkinson patients. Parkinsonism Relat Disord 2005;11:253-256 (Pubitemid 40692838)
22. Ostrem JL, Kang GA, Subramanian I, Guarnieri M, Hubble J, Rabinowicz AL, Bronstein J. The effect of entacapone on homocysteine levels in Parkinson disease. Neurology 2005;64:1482. (Pubitemid 40570535)
23. Jenner P. Oxidative stress in Parkinson's disease. Ann Neurol 2003;53 Suppl 3:S26-S36. (Pubitemid 36368560)
24. 2-treated U937 monocytes. Free Radic Biol Med 2004;36:423-428
25. Nijhout HF, Gregory JF, Fitzpatrick C, Cho E, Lamers KY, Ulrich CM, Reed MC. A mathematical model gives insights into the effects of vitamin B-6 deficiency on 1-carbon and glutathione metabolism. J Nutr 2009;139:784-791
26. Gurol ME, Irizarry MC, Smith EE, Raju S, az- Arrastia R, Bottiglieri T, et al. Plasma betaamyloid and white matter lesions in AD, MCI, and cerebral amyloid angiopathy. Neurology 2006;66:23-29
27. Bush AI, Tanzi RE. Alzheimer disease-related abnormalities of amyloid beta precursor protein isoforms in the platelet: the brain's delegate in the periphery? Arch Neurol 1998;55:1179-1180
28. Padovani A, Pastorino L, Borroni B, Colciaghi F, Rozzini L, Monastero R, et al. Amyloid precursor protein in platelets: a peripheral marker for the diagnosis of sporadic AD. Neurology 2001;57:2243-2248 (Pubitemid 34016458)
29. Casoli T, Di SG, Giorgetti B, Grossi Y, Balietti M, Fattoretti P, Bertoni-Freddari C. Release of beta-amyloid from high-density platelets: implications for Alzheimer's disease pathology. Ann N Y Acad Sci 2007;1096:170-178 (Pubitemid 47092510)
30. Fuso A, Seminara L, Cavallaro RA, D'Anselmi F, Scarpa S. S-adenosylmethionine/homocysteine cycle alterations modify DNA methylation status with consequent deregulation of PS1 and BACE and beta-amyloid production. Mol Cell Neurosci 2005;28:195-204. (Pubitemid 39656023)
31. Hung AY, Haass C, Nitsch RM, Qiu WQ, Citron M, Wurtman RJ, et al. Activation of protein kinase C inhibits cellular production of the amyloid beta-protein. J Biol Chem 1993;268:22959-22962 (Pubitemid 23327996)
32. Lotharius J, Barg S, Wiekop P, Lundberg C, Raymon HK, Brundin P. Effect of mutant alphasynuclein on dopamine homeostasis in a new human mesencephalic cell line. J Biol Chem 2002;277:38884-38894 (Pubitemid 35154753)
33. Yi P, Melnyk S, Pogribna M, Pogribny IP, Hine RJ, James SJ. Increase in plasma homocysteine associated with parallel increases in plasma S-adenosylhomocysteine and lymphocyte DNA hypomethylation. J Biol Chem 2000;275:29318-29323 (Pubitemid 32043802)
34. Bonsch D, Reulbach U, Bayerlein K, Hillemacher T, Kornhuber J, Bleich S. Elevated alpha synuclein mRNA levels are associated with craving in patients with alcoholism. Biol Psychiatry 2004;56:984-986 (Pubitemid 39643058)
35. Purohit V, Russo D. Cellular and molecular mechanisms of alcoholic hepatitis: introduction and summary of the symposium. Alcohol 2002;27:3-6. (Pubitemid 34626476)
36. Vigneswara V, Lowenson JD, Powell CD, Thakur M, Bailey K, Clarke S, et al. Proteomic identification of novel substrates of a protein isoaspartyl methyltransferase repair enzyme. J Biol Chem 2006;281:32619-32629 (Pubitemid 46036817)
37. Clarke S. Protein carboxyl methyltransferases: two distinct classes of enzymes. Annu Rev Biochem 1985;54:479-506. (Pubitemid 15073655)
38. Kosugi S, Furuchi T, Katane M, Sekine M, Shirasawa T, Homma H. Suppression of protein L-isoaspartyl (D-aspartyl) methyltransferase results in hyperactivation of EGF-stimulated MEK-ERK signaling in cultured mammalian cells. Biochem Biophys Res Commun 2008;371:22-27
39. Clough RL, Stefanis L. A novel pathway for transcriptional regulation of alpha-synuclein. FASEB J 2007;21:596-607. (Pubitemid 46213506)
40. de Almeida LM, Funchal C, Pelaez PL, Pessutto FD, Loureiro SO, Vivian L, et al. Effect of propionic and methylmalonic acids on the in vitro phosphorylation of intermediate filaments from cerebral cortex of rats during development. Metab Brain Dis 2003;18:207-219 (Pubitemid 37187859)